Subjects recruited: 220 adults of either sex with uncomplicated upper respiratory tract infection (URTI)

Dose: 200 mg/day in two divided doses

Results:

The efficacy was evaluated on the basis of visual analogue scale scores of various symptoms of URTI, like cough, expectoration, nasal discharge, headache, fever, sore throat, earache, malaise/fatigue and sleep disturbance on day 1, 3 and 5.

In both the groups (placebo and  KALMCOLD^TM  ), mean scores of all symptoms showed a decreasing trend from day 1 to day 3 and day 5 but from day 3 to day 5 most of the symptoms in placebo treated group either remained constant (cough, headache and earache) or got aggravated (sore throat and sleep disturbance) whereas in  KALMCOLD^TM treated group all symptoms showed a decreasing trend.

The comparison of effect of  KALMCOLD^TM over placebo was found to be significant (p ≤ 0.05) for all parameters except earache and the overall effect size of  KALMCOLD^TM on symptoms was found to be significant (p ≤ 0.05) and 2.1 times or 52.7% higher than placebo.

 The study had low level of adverse events in both  KALMCOLD^TM and placebo groups.